Pith. sign in

REVIEW 3 major objections 7 minor 72 references

NSUN2 as a potential prognostic as well as therapeutic target in cancer by regulating m5C modification

T0 review · 3 major / 7 minor · reviewed 2026-08-07 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read This review argues that NSUN2, the main m5C RNA methyltransferase, is overexpressed across many cancers, tracks with poor survival, and should be tested as a prognostic marker and therapeutic target.

desk verdict A serviceable review that accurately summarizes the NSUN2 literature, but its one original element (non-significant TCGA survival curves) is presented as corroboration on the strength of a belief about sample size, not evidence. read the letter →

arxiv 2506.06673 v1 pith:FA7ZMEFV submitted 2025-06-07 q-bio.BM

Zifang He , Longtao Yang , Peiyao Ma This is my paper
classification q-bio.BM
keywords NSUN2m5CmodificationRNAmethylationcancerprognosistherapeutictargetbiomarkerTCGAsurvivalanalysisoncogene
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This review makes the case that NSUN2, the principal enzyme that writes m5C marks on RNA, is a common feature of cancer and a clinically useful one. It argues that NSUN2 is overexpressed in gastric, colorectal, lung, bladder, prostate, endometrial, and cervical cancers, that high expression accompanies larger tumors and more advanced stages, and that patients with high NSUN2 tend to have worse overall, progression-free, or disease-free survival. The paper also describes a consistent mechanism: NSUN2 deposits m5C on specific messenger RNAs, stabilizing or increasing their translation, and in that way drives proliferation, migration, and invasion. The authors' own survival analyses from public databases show the expected trend but are not statistically significant, a limitation they attribute to small sample size. The payoff, if the pattern holds, is that NSUN2 expression could serve as a prognostic indicator and NSUN2 itself as a target for therapy across multiple cancer types.

What carries the argument

The central object is NSUN2, an NOP2/Sun-domain RNA methyltransferase that catalyzes 5-methylcytosine (m5C) modification of RNA by transferring methyl groups to cytosine residues. The argument turns on the writer–reader system for m5C: NSUN2 deposits the mark, proteins such as ALYREF read it, and the mark alters messenger RNA stability, export, or translation efficiency. The paper uses enzyme-dead mutant constructs, RNA bisulfite sequencing, knockdown and overexpression cell lines, mouse xenograft models, and survival analyses of public tumor cohorts to connect NSUN2's enzymatic activity to the expression of downstream targets and, ultimately, to tumor progression and patient outcome.

What would settle it

A well-powered prospective study with multivariable adjustment for tumor stage, grade, age, and treatment that found no independent association between NSUN2 expression and overall or progression-free survival in these cancer types would refute the prognostic claim; a clinical trial in which NSUN2 inhibition changed neither tumor growth nor patient survival would refute the therapeutic claim.

Watch

Extended reading notes

Core claim

On its own terms, the paper claims that NSUN2 represents a critical prognostic marker for cancer and a promising therapeutic target. The evidence assembled is that NSUN2 is consistently upregulated in tumor tissue relative to normal tissue across at least seven cancer types; that its expression correlates with tumor size, grade, and TNM stage in several of them; and that high expression is associated with shorter survival in Kaplan–Meier and Cox analyses, with the review's own TCGA and GEO analyses showing the same direction. Mechanistically, the paper argues the oncogenic effect is m5C-dependent: wild-type NSUN2, but not an enzyme-dead mutant, restores proliferation and metastasis in NSUN2-deficient cells, and knockdown sharply reduces m5C peaks on mRNA. The claimed consequence is that reducing NSUN2 expression or blocking its methyltransferase activity could improve patient prognosis.

Load-bearing premise

The load-bearing premise is that the survival trends the authors see in their own analyses, which they acknowledge are not statistically significant, would become clear and meaningful with larger samples, and that high NSUN2 expression is a cause of poor prognosis rather than a coincidental correlate.

Editorial extensions

If this is right

  • If the pattern holds, NSUN2 expression could be added to clinical staging to identify cancer patients at higher risk of progression.
  • Blocking NSUN2's methyltransferase activity, or disrupting the m5C marks it writes, could slow tumor growth across multiple cancer types.
  • Because the oncogenic effect appears to require m5C, drugs targeting m5C writers or readers may be more broadly useful than drugs aimed at any single downstream gene.
  • The consistent survival association suggests NSUN2 could be incorporated into prognostic panels and used to stratify patients in future trials.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The authors leave implicit that their non-significant survival analyses mean the prognostic claim is not yet definitive; a reader should treat it as a testable hypothesis rather than an established clinical fact.
  • A natural extension the paper does not develop is to measure m5C levels or NSUN2's target mRNAs directly in patient samples, which could show whether expression level alone or the specific m5C target profile predicts survival better.
  • If NSUN2 is validated as a driver, an important open question is whether its role is consistent across cancer types or context-dependent, since some of the cited associations may reflect passenger effects of broader epigenetic dysregulation.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

3 major / 7 minor

Summary. This manuscript is a review-style paper claiming that the RNA methyltransferase NSUN2 is overexpressed in multiple cancers, promotes tumor progression through m5C modification, and is associated with poor patient prognosis. The authors synthesize published mechanistic and clinical studies for gastric, colorectal, lung, bladder, prostate, endometrial, and cervical cancer, and they present original TCGA-based Kaplan-Meier survival analyses (Figs. 4-7) as additional corroboration. The paper concludes that NSUN2 represents a critical prognostic marker and a promising therapeutic target. The review is broad and cites much of the relevant literature, but the authors' own survival analyses are explicitly non-significant and lack methodological detail, and the conclusions overstate the strength of this evidence.

Significance. If the central claim is correct, NSUN2 could serve as a clinically useful prognostic biomarker and a target for cancer therapy across multiple tumor types. The manuscript brings together a substantial body of literature and provides a useful overview of the mechanisms linking NSUN2, m5C modification, and cancer progression. However, the paper's own original contribution consists of four non-significant survival analyses that are presented as supporting evidence, and the text contains factual and citation errors. The prognostic and therapeutic claim is plausible on the basis of external studies, but the manuscript's own evidence base is fragile and the conclusion as written overstates what the presented data show.

major comments (3)
  1. [Sections 2.1.2, 2.3.1, 2.4.1; Figs. 4-7] The authors' own TCGA survival analyses are non-significant and are used to corroborate the prognostic claim. In Section 2.1.2 the text states, 'We believe that, when the number of samples is sufficiently large, it will surely make this trend is more obvious,' and similar statements appear in Sections 2.3.1 and 2.4.1. No data cut-off, covariate adjustment, hazard ratio, confidence interval, or software is reported for any of the four Kaplan-Meier analyses. A non-significant trend in the hypothesized direction is weak, inconclusive evidence, and the unsupported belief that a larger sample would 'surely' produce significance is not a substitute for a power analysis or for consistent significant results across cohorts. This is load-bearing because the Conclusion asserts that 'NSUN2 represents a critical prognostic marker for cancer.' Please either provide full statistical reporting with a realistic power calculation, or remove these analyses and explicitly temper the conclusion to reflect that the authors' own data do not provide statistically significant support.
  2. [Reference [73] and Section 2.1.2] Reference [73] is malformed: it begins with a title fragment, contains the word 'cancernner,' and has an inconsistent citation format. More seriously, it is cited in Section 2.1.2 to support the statement that in colorectal cancer, patients with high NSUN2 expression had lower disease-free survival and that NSUN2 is an independent prognostic indicator for overall survival, but the reference title indicates the study is about NSUN2 in non-small cell lung cancer, not colorectal cancer. This citation mismatch undermines the specific prognostic claim for CRC. Please verify the intended source and correct the reference or the cited claim.
  3. [Introduction, Section 3, Fig. 3 legend] The Introduction and Conclusion state that the review covers ovarian cancer, and the Fig. 3 legend lists ovarian cancer and osteosarcoma, but the main text contains no section on ovarian cancer (and no section on osteosarcoma either). The cancers actually discussed are gastric, colorectal, lung, bladder, prostate, endometrial, and cervical. This inconsistency should be resolved by either adding the missing content or removing those mentions.
minor comments (7)
  1. [Abbreviation list and Section 2.2.1] The abbreviation 'NSCLC' is defined as 'Non-cancerous' and Section 2.2.1 states that 'approximately 85% of lung cancer cases are classified as non-cancerous (NSCLC).' NSCLC stands for non-small cell lung cancer, not non-cancerous; this is a factual error that should be corrected.
  2. [Introduction] The text refers to 'demethylases (“wipers”)'; the standard term is 'erasers' rather than 'wipers.'
  3. [Section 2.1.1] The phrase 'RNA double sequencing analysis' likely should be 'RNA sequencing analysis' or 'RNA bisulfite sequencing analysis'; please clarify.
  4. [Reference list] Several references are duplicated: [9] and [32] are the same article, [17] and [10] are the same article, and [33] duplicates [31]. Please deduplicate the bibliography.
  5. [Figures 4-7] The Kaplan-Meier figure legends do not report the cut-off used to define high versus low NSUN2 expression, the statistical test, the p-value, or the number of events. Adding these details would improve reproducibility and interpretation.
  6. [Abbreviation list] The abbreviation 'USUN' is listed but not used or defined in the text; please remove or explain it.
  7. [Abstract and Section 1] The phrase 'm5C modification is a type of RNA methylation modification' is imprecise because m5C also occurs in DNA; the text later acknowledges this, but the abstract should be tightened.

Circularity Check

0 steps flagged · score 0.0 of 10

No circular derivation: this is a review that assembles external evidence; the non-significant TCGA survival trends are weak evidence, not circular inputs.

full rationale

This paper is a narrative review, not a derivation or modeling study. It contains no fitted parameters, no normalization or rescaling steps, and no equations whose outputs coincide with inputs by construction. The authors' own TCGA survival analyses (Sections 2.1.2, 2.3.1, and 2.4.1) are explicitly reported as not statistically significant, and the statement 'We believe that, when the number of samples is sufficiently large, it will surely make this trend is more obvious' is an unsupported statistical assumption rather than a circular reduction. The review's prognostic conclusion rests on cited external studies (e.g., refs [27], [44], [60], [73], [74]) that independently performed survival analyses; those citations are not self-citations, and nothing in the argument reduces to the authors' own prior work or definitions. Overstatement of weak evidence is a correctness risk, not circularity. Therefore no significant circularity is present.

Assumptions & free parameters 0 free parameters · 3 assumptions · 0 invented entities

The review depends entirely on the reliability of the cited experimental studies and public databases. It introduces no new models or entities. Its own statistical analyses are presented with an unsupported assumption about future significance.

assumptions (3)
  • domain assumption The cited experimental studies (e.g., refs 27, 38, 43, 44, 54, 60, 64) correctly demonstrate that NSUN2 promotes cancer proliferation, migration, invasion, and poor prognosis through m5C modification.
    The review's central conclusion is entirely dependent on accepting the results of prior studies it cites, without independent verification.
  • domain assumption TCGA and GEO datasets are reliable and representative for cancer expression and survival analysis.
    The authors' own survival analyses (Figs. 4-7) rely on TCGA data without methodological validation or discussion of batch effects, clinical covariates, or platform biases.
  • ad hoc to paper The authors' non-significant survival trends would become significant with larger sample sizes.
    The authors state 'We believe that, when the number of samples is sufficiently large, it will surely make this trend is more obvious' (CRC section, Section 2.1.2), an unproven statistical assumption with no power analysis.

how reviews work

0 comments
Cite this review

Pith. "Pith review of NSUN2 as a potential prognostic as well as therapeutic target in cancer by regulating m5C modification." pith.science (2026). https://pith.science/paper/FA7ZMEFV

@misc{pith2026250606673,
  author       = {Pith},
  title        = {Pith review of: NSUN2 as a potential prognostic as well as therapeutic target in cancer by regulating m5C modification},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/FA7ZMEFV}},
  note         = {Machine review of arXiv:2506.06673}
}
read the original abstract

m5C modification is a type of RNA methylation modification, and its major methyltransferase, NSUN2, catalyzes m5C modification. NSUN2 is overexpressed in a variety of cancers, and it affects the metabolism of RNA from target genes by affecting the level of m5C modification in cancer cells, which in turn promotes the development of cancers and is associated with poor prognosis. This review summarizes the mechanisms by which NSUN2 and m5C play a pro-cancer role in various cancers, and the relationship between NSUN2 and the prognosis of various cancers, with the aim of identifying NSUN2 as a prognostic indicator and a target for future cancer therapy, and to provide a clearer therapeutic idea and direction for the future treatment of cancer.

Figures

Figures reproduced from arXiv: 2506.06673 by the authors.

Figure 1
Figure 1. schematic representation of the structural location of RNA modifications on genes and the DNMT and NSUN families as methyltransferases promoting m5C formation, m5C is more aggregated in the 5'UTR and 3'UTR regions, and the DNMT and NSUN families can catalyze the process of adding methyl groups to genes, i.e., catalyze the formation of m5C. (Created in https://BioRender.com) [PITH_FULL_IMAGE:figures/full_fig_p020_1.png] view at source ↗
Figure 2
Figure 2. The pan-cancer expression status of NSUN2 mRNA in TCGA database (normal vs. tumor) shows that NSUN2 is overexpressed in a variety of cancers compared to normal tissues [PITH_FULL_IMAGE:figures/full_fig_p020_2.png] view at source ↗

Discussion (0). Sign in to comment.

Reference graph

Works this paper leans on

72 extracted references · 72 canonical work pages

  1. [73]

    Clin Transl Med

    5 -Methylcytosine transferase NSUN2 drives NRF2 -mediated ferroptosis Running title: no more than 70 characters including spaces 20 20 resistance in non-small cell lung cancernner. Clin Transl Med. 2025 Apr;15(4): e70282. doi: 10.1002/ctm2.70282. PMID: 40156167; PMCID: PMC11953055

    work page doi:10.1002/ctm2.70282 2025

  2. [54]

    5 -Methylcytosine transferase NSUN2 drives NRF2 -mediated ferroptosis resistance in non - small cell lung cancer

    Chen Y, Jiang Z, Zhang C, Zhang L, Chen H, Xiao N, et al. 5 -Methylcytosine transferase NSUN2 drives NRF2 -mediated ferroptosis resistance in non - small cell lung cancer. J Biol Chem. 2024 Apr;300(4):106793

    work page 2024

  3. [1]

    RNA modifications and structures cooperate to guide RNA-protein interactions

    Lewis CJ, Pan T, Kalsotra A. RNA modifications and structures cooperate to guide RNA-protein interactions. Nat Rev Mol Cell Biol. 2017 Mar;18(3):202- 210

    work page 2017

  4. [2]

    Cancer survival in Europe 1999 -2007 by country and age: results of EUROCARE--5-a population-based study

    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999 -2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014 Jan;15(1):23-34

    work page 1999

  5. [3]

    Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Running title: no more than 70 characters including spaces 14 14 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249

    work page 2020

  6. [4]

    Trends in the Incidence of Fatal Prostate Cancer in the United States by Race

    Kelly SP, Rosenberg PS, Anderson WF, Andreotti G, Younes N, Cleary SD, Cook MB. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol. 2017 Feb;71(2):195-201

    work page 2017

  7. [5]

    The role of DNA methylation in epigenetics of aging

    Unnikrishnan A, Freeman WM, Jackson J, Wren JD, Porter H, Richardson A. The role of DNA methylation in epigenetics of aging. Pharmacol Ther. 2019 Mar; 195:172-185

    work page 2019

  8. [6]

    Aberrant NSUN2 -mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma

    Sun Z, Xue S, Zhang M, Xu H, Hu X, Chen S, et al. Aberrant NSUN2 -mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. Oncogene. 2020 Nov;39(45):6906-6919

    work page 2020

Show all 72 references
  1. [7]

    MODOMICS: a database of RNA modification pathways

    Boccaletto P, Stefaniak F, Ray A, Cappannini A, Mukherjee S, Purta E, et al. MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 2022 Jan 7;50(D1): D231-D235

    2021

  2. [8]

    NSUN2 -Mediated m5C Methylation and METTL3/METTL14 -Mediated m6A Methylation Cooperatively Enhance p21 Translation

    Li Q, Li X, Tang H, Jiang B, Dou Y, Gorospe M, et al. NSUN2 -Mediated m5C Methylation and METTL3/METTL14 -Mediated m6A Methylation Cooperatively Enhance p21 Translation. J Cell Biochem. 2017 Sep;118(9):2587-2598

    2017

  3. [11]

    RNA methylation in mammalian development and cancer

    Song P, Tayier S, Cai Z, Jia G. RNA methylation in mammalian development and cancer. Cell Biol Toxicol. 2021 Dec;37(6):811-831

    2021

  4. [12]

    Predictive model for the 5 -year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm

    Jiang J, Pan H, Li M, Qian B, Lin X, Fan S. Predictive model for the 5 -year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm. Sci Rep. 2021 Mar 10;11(1):5542

    2021

  5. [13]

    NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m5C methylation

    Yang M, Wei R, Zhang S, Hu S, Liang X, Yang Z, et al. NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m5C methylation. Cell Death Dis. 2023 Feb 15;14(2):125

    2023

  6. [14]

    hiCLIP reveals the in vivo atlas of mRNA secondary structures recognized by Running title: no more than 70 characters including spaces 15 15 Staufen 1

    Sugimoto Y, Vigilante A, Darbo E, Zirra A, Militti C, D'Ambrogio A, et al. hiCLIP reveals the in vivo atlas of mRNA secondary structures recognized by Running title: no more than 70 characters including spaces 15 15 Staufen 1. Nature. 2015 Mar 26;519(7544):491-4

    2015

  7. [15]

    The RNA Modification Database, RNAMDB: 2011 update

    Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, et al. The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res. 2011 Jan;39(Database issue): D195-201

    2011

  8. [16]

    Eukaryotic 5-methylcytosine (m⁵C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease

    Bohnsack KE, Höbartner C, Bohnsack MT. Eukaryotic 5-methylcytosine (m⁵C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease. Genes (Basel). 2019 Jan 30;10(2):102

    2019

  9. [17]

    Role of Main RNA Methylation in Hepatocellular Carcinoma: N6 -Methyladenosine, 5 - Methylcytosine, and N1-Methyladenosine

    Xu Y, Zhang M, Zhang Q, Yu X, Sun Z, He Y, et al. Role of Main RNA Methylation in Hepatocellular Carcinoma: N6 -Methyladenosine, 5 - Methylcytosine, and N1-Methyladenosine. Front Cell Dev Biol. 2021 Nov 30; 9:767668

    2021

  10. [18]

    Widespread occurrence of 5-methylcytosine in human coding and non- coding RNA

    Squires JE, Patel HR, Nousch M, Sibbritt T, Humphreys DT, Parker BJ, et al. Widespread occurrence of 5-methylcytosine in human coding and non- coding RNA. Nucleic Acids Res. 2012 Jun;40(11):5023-33

    2012

  11. [19]

    NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation

    Zhang X, An K, Ge X, Sun Y, Wei J, Ren W, et al. NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation. Breast Cancer Res. 2024 Jun 6;26(1):94

    2024

  12. [20]

    NSUN2 -mediated m5C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression

    Zuo S, Li L, Wen X, Gu X, Zhuang A, Li R, et al. NSUN2 -mediated m5C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression. Clin Transl Med. 2023 May;13(5): e1273

    2023

  13. [21]

    Exploration of YBX1 role in the prognostic value and immune characteristics by single -cell and bulk sequencing analysis for liver hepatocellular carcinoma

    Zhang Q, Zhu B, Yang H, Li F, Qu Y, Lu L, et al. Exploration of YBX1 role in the prognostic value and immune characteristics by single -cell and bulk sequencing analysis for liver hepatocellular carcinoma. J Gene Med. 2024 Mar;26(3): e3680

    2024

  14. [22]

    Overview of distinct 5 -methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues

    Zhang Q, Zheng Q, Yu X, He Y, Guo W. Overview of distinct 5 -methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues. J Transl Med. 2020 Jun 22;18(1):245

    2020

  15. [23]

    Publisher Correction: Post -transcriptional gene regulation by mRNA modifications

    Zhao BS, Roundtree IA, He C. Publisher Correction: Post -transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2018 Dec;19(12):808. doi: 10.1038/s41580- 018-0075-1. Erratum for: Nat Rev Mol Cell Biol. 2017 Jan;18(1):31-42

    2018 doi

  16. [24]

    Recent insights into RNA m5C methylation modification in hepatocellular carcinoma

    Li D, Liu Y, Yang G, He M, Lu L. Recent insights into RNA m5C methylation modification in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189223

    2024

  17. [25]

    Dynamic Transcriptomic M5C and Its Regulatory Role in RNA Processing

    Chen YS, Yang WL, Zhao YL, Yang YG. Dynamic Transcriptomic M5C and Its Regulatory Role in RNA Processing. Wiley Interdiscip Rev RNA (2021) 12 (4): Running title: no more than 70 characters including spaces 16 16 e1639

    2021

  18. [26]

    Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer

    Alldredge JK, Tewari KS. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist. 2016 May;21(5):576-85

    2016

  19. [27]

    NSUN2 modified by SUMO- 2/3 promotes gastric cancer progression and regulates mRNA m5C methylation

    Hu Y, Chen C, Tong X, Chen S, Hu X, Pan B, et al. NSUN2 modified by SUMO- 2/3 promotes gastric cancer progression and regulates mRNA m5C methylation. Cell Death Dis. 2021 Sep 9;12(9):842

    2021

  20. [28]

    m5C RNA Methylation Primarily Affects the ErbB and PI3K -Akt Signaling Pathways in Gastrointestinal Cancer

    Xiang S, Ma Y, Shen J, Zhao Y, Wu X, Li M, et al. m5C RNA Methylation Primarily Affects the ErbB and PI3K -Akt Signaling Pathways in Gastrointestinal Cancer. Front Mol Biosci. 2020 Dec 7; 7:599340

    2020

  21. [29]

    Loss of 5-methylcytosine alters the biogenesis of vault-derived small RNAs to coordinate epidermal differentiation

    Sajini AA, Choudhury NR, Wagner RE, Bornelöv S, Selmi T, Spanos C, et al. Loss of 5-methylcytosine alters the biogenesis of vault-derived small RNAs to coordinate epidermal differentiation. Nat Commun. 2019 Jun 11;10(1):2550

    2019

  22. [30]

    Why US Cervical Cancer Survival Rates Haven't Improved for Decades

    Suran M. Why US Cervical Cancer Survival Rates Haven't Improved for Decades. JAMA. 2022 May 24;327(20):1943-1945

    2022

  23. [32]

    T h e r o l e o f m 6 A , m 5 C a n d Ψ R N A modifications in cancer: Novel therapeutic opportunities

    Nombela P, Miguel -L ó p e z B , B l a n c o S . T h e r o l e o f m 6 A , m 5 C a n d Ψ R N A modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021 Jan 18;20(1):18

    2021

  24. [33]

    The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer

    Chellamuthu A, Gray SG. The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer. Cells. 2020 Jul 22;9(8):1758

    2020

  25. [34]

    Cancer statistics in China, 2015

    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32

    2015

  26. [35]

    5 -methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m5C reader

    Yang X, Yang Y, Sun BF, Chen YS, Xu JW, Lai WY, et al. 5 -methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m5C reader. Cell Res. 2017 May;27(5):606-625

    2017

  27. [36]

    [Report of Cancer Incidence and Mortality in China, 2014]

    Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW, Zeng HM, et al. [Report of Cancer Incidence and Mortality in China, 2014]. Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. Chinese

    2014

  28. [37]

    m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming

    Fang L, Huang H, Lv J, Chen Z, Lu C, Jiang T, et al. m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming. Cell Death Dis. 2023 Aug 15;14(8):520

    2023

  29. [38]

    Mei L, Shen C, Miao R, Wang JZ, Cao MD, Zhang YS, et al. RNA methyltransferase NSUN2 promotes gastric cancer cell proliferation by Running title: no more than 70 characters including spaces 17 17 repressing p57Kip2 by an m5C-dependent manner. Cell Death Dis. 2020 Apr 24;11(4):270

    2020

  30. [39]

    NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs

    Hussain S, Sajini AA, Blanco S, Dietmann S, Lombard P, Sugimoto Y, et al. NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs. Cell Rep. 2013 Jul 25;4(2):255-61

    2013

  31. [40]

    RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer

    Liu X, Wei Q, Yang C, Zhao H, Xu J, Mobet Y, et al. RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. Exp Mol Med. 2024 Mar;56(3):600-615

    2024

  32. [41]

    Colorectal cancer statistics, 2020

    Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 May;70(3):145- 164

    2020

  33. [42]

    The Link between Food Environment and Colorectal Cancer: A Systematic Review

    Masdor NA, Mohammed Nawi A, Hod R, Wong Z, Makpol S, Chin SF. The Link between Food Environment and Colorectal Cancer: A Systematic Review. Nutrients. 2022 Sep 23;14(19):3954

    2022

  34. [43]

    Metabolic Recoding of NSUN2-Mediated m5C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m5C -ENO1 Positive Feedback Loop

    Chen B, Deng Y, Hong Y, Fan L, Zhai X, Hu H, et al. Metabolic Recoding of NSUN2-Mediated m5C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m5C -ENO1 Positive Feedback Loop. Adv Sci (Weinh). 2024 Jul;11(28): e2309840

    2024

  35. [44]

    NSUN2 promotes colorectal cancer progression by enhancing SKIL mRNA stabilization

    Zou S, Huang Y, Yang Z, Zhang J, Meng M, Zhang Y, et al. NSUN2 promotes colorectal cancer progression by enhancing SKIL mRNA stabilization. Clin Transl Med. 2024 Mar;14(3): e1621

    2024

  36. [45]

    m5C regulator -mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine

    Chen B, Xi Y, Zhao J, Hong Y, Tian S, Zhai X, Chen Q, Ren X, Fan L, Xie X, Jiang C. m5C regulator -mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine. Front Immunol. 2022 Dec 1; 13:1049435

    2022

  37. [46]

    A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients

    Liu J, Dou M, Liu X, Lu Y, Lu W. A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients. J Cancer Res Clin Oncol. 2023 Oct;149(13):11995-12012

    2023

  38. [47]

    Identification and validation of a novel prognosis model based on m5C -related long non -coding RNAs in colorectal cancer

    Di Z, Xu G, Ding Z, Li C, Song J, Huang G, et al. Identification and validation of a novel prognosis model based on m5C -related long non -coding RNAs in colorectal cancer. Cancer Cell Int. 2023 Sep 5;23(1):196

    2023

  39. [48]

    Role of m5 C RNA methylation regulators in colorectal cancer prognosis and immune microenvironment

    Fang X, Miao C, Zeng T, Chu W, Zheng Y, Sun X, et al. Role of m5 C RNA methylation regulators in colorectal cancer prognosis and immune microenvironment. J Clin Lab Anal. 2022 Apr;36(4): e24303

    2022

  40. [49]

    Chen Z, Li Q, Lin Y, Lin S, Gao J, Chen S. m5C regulator-mediated methylation Running title: no more than 70 characters including spaces 18 18 modification phenotypes characterized by distinct tumor microenvironment immune heterogenicity in colorectal cancer. Sci Rep. 2023 Jul...

    2023

  41. [50]

    OC, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology,

    Deborah K. “OC, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network 19, no. 2 (February 2, 2021): 191–226

    2020

  42. [51]

    The biology and management of non - small cell lung cancer

    Herbst RS, Morgensztern D, Boshoff C. The biology and management of non - small cell lung cancer. Nature. 2018 Jan 24;553(7689):446-454

    2018

  43. [52]

    Current knowledge of small cell lung cancer transformation from non-small cell lung cancer

    Giaccone G, He Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer. Semin Cancer Biol. 2023 Sep; 94:1-10

    2023

  44. [53]

    Non-small cell lung cancer: current treatment and future advances

    Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun;5(3):288-300

    2016

  45. [55]

    RNA methyltransferase NSUN2 -mediated m5C methylation promotes Cr (VI) - induced malignant transformation and lung cancer by accelerating metabolism reprogramming

    Zhang RK, Li Y, Sun FL, Zhou ZH, Xie YX, Liu WJ, et al. RNA methyltransferase NSUN2 -mediated m5C methylation promotes Cr (VI) - induced malignant transformation and lung cancer by accelerating metabolism reprogramming. Environ Int. 2024 Oct; 192:109055

    2024

  46. [56]

    Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice

    van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023 May;20(5):287-304

    2023

  47. [57]

    Cancer statistics, 2022

    Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33

    2022

  48. [58]

    Improving Systemic Chemotherapy for Bladder Cancer

    Rose TL, Milowsky MI. Improving Systemic Chemotherapy for Bladder Cancer. Curr Oncol Rep. 2016 May;18(5):27

    2016

  49. [59]

    Increased survival of patients aged 0-29 years with osteosarcoma: A period analysis, 1984-2013

    Wu J, Sun H, Li J, Guo Y, Zhang K, Lang C, et al. Increased survival of patients aged 0-29 years with osteosarcoma: A period analysis, 1984-2013. Cancer Med. 2018 Aug;7(8):3652-3661

    1984

  50. [60]

    NSUN2 -mediated R-loop stabilization as a key driver of bladder cancer progression and cisplatin sensitivity

    Wu Y, Ying Y, Zhang F, Shu X, Qi Z, Wang J, et al. NSUN2 -mediated R-loop stabilization as a key driver of bladder cancer progression and cisplatin sensitivity. Cancer Lett. 2024 Dec 26; 611:217416

    2024

  51. [61]

    Wang N, Chen RX, Deng MH, Wei WS, Zhou ZH, Ning K, et al. m5C-dependent cross-regulation between nuclear reader ALYREF and writer NSUN2 promotes urothelial bladder cancer malignancy through facilitating RABL6/TK1 mRNAs splicing and stabilization. Cell Death Dis. 2023 Feb Runni...

    2023

  52. [62]

    Trends in the Incidence of Fatal Prostate Cancer in the United States by Race

    Kelly SP, Rosenberg PS, Anderson WF, Andreotti G, Younes N, Cleary SD, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol. 2017 Feb;71(2):195-201

    2017

  53. [63]

    Upregulation of LRRC8A by m5C modification -mediated mRNA stability suppresses apoptosis and facilitates tumorigenesis in cervical cancer

    Chen Y, Zuo X, Wei Q, Xu J, Liu X, Liu S, et al. Upregulation of LRRC8A by m5C modification -mediated mRNA stability suppresses apoptosis and facilitates tumorigenesis in cervical cancer. Int J Biol Sci. 2023 Jan 1;19(2):691-704

    2023

  54. [64]

    Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression

    Zhu W, Wan F, Xu W, Liu Z, Wang J, Zhang H, et al. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression. Clin Transl Med. 2022 Sep;12(9): e1028

    2022

  55. [65]

    Multi-omics analysis of expression and prognostic value of NSUN members in prostate cancer

    Sun G, Ma S, Zheng Z, Wang X, Chen S, Chang T, et al. Multi-omics analysis of expression and prognostic value of NSUN members in prostate cancer. Front Oncol. 2022 Aug 1; 12:965571

    2022

  56. [66]

    Tan X, Cai Z, Chen G, Cai C, Chen J, Liang Y, et al. Identification and verification of an ALYREF -involved 5 -methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies. Discov Oncol. 2023 May 8;14(1):62

    2023

  57. [67]

    Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma

    Xu Z, Chen S, Zhang Y, Liu R, Chen M. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma. Front Immunol. 2022 May 4; 13:869759

    2022

  58. [68]

    Endometrial cancer

    Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505

    2005

  59. [69]

    Evaluation of Survival, Recurrence Patterns and Adjuvant Therapy in Surgically Staged High -Grade Endometrial Cancer with Retroperitoneal Metastases

    McEachron J, Marshall L, Zhou N, Tran V, Kanis MJ, Gorelick C, et al. Evaluation of Survival, Recurrence Patterns and Adjuvant Therapy in Surgically Staged High -Grade Endometrial Cancer with Retroperitoneal Metastases. Cancers (Basel). 2021 Apr 23;13(9):2052

    2021

  60. [70]

    Rauh -Hain, M.G

    J.A. Rauh -Hain, M.G. Del Carmen. Treatment for advanced and recurrent endometrial carcinoma: combined modalities, Oncol. 15 (8) (2010) 852–861

    2010

  61. [71]

    RNA 5 -Methylcytosine regulators are associated with cell adhesion and predict prognosis of endometrial cancer

    Yang S, Luo Y, Zhou D, Xiang J, Xi X. RNA 5 -Methylcytosine regulators are associated with cell adhesion and predict prognosis of endometrial cancer. Transl Cancer Res. 2023 Oct 31;12(10):2556-2571

    2023

  62. [72]

    Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review

    Jin Z, Sheng J, Hu Y, Zhang Y, Wang X, Huang Y. Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review. Front Genet. 2023 Oct 11; 14:1247309

    2023

  63. [74]

    Epigenetically upregulated NSUN2 confers ferroptosis resistance in endometrial cancer via mC modification of SLC7A11 mRNA

    Chen SJ, Zhang J, Zhou T, Rao SS, Li Q, Xiao LY, Wei ST, Zhang HF. Epigenetically upregulated NSUN2 confers ferroptosis resistance in endometrial cancer via mC modification of SLC7A11 mRNA. Redox Biol. 2024 Feb; 69:102975. doi: 10.1016/j.redox.2023.102975. Epub 2023 Nov 29. PM...

    2024

  64. [75]

    Distinct Roles of m5C RNA Methyltransferase NSUN2 in Major Gynecologic Cancers

    Wang L, Zhang J, Su Y, Maimaitiyiming Y, Yang S, Shen Z, Lin S, Shen S, Zhan G, Wang F, Hsu CH, Cheng X. Distinct Roles of m5C RNA Methyltransferase NSUN2 in Major Gynecologic Cancers. Front Oncol. 2022 Feb 25; 12:786266. doi: 10.3389/fonc.2022.786266. PMID: 35280737; PMCID: P...

    2022

Pith tools

Reviewed August 7, 2026 · model on record in the stance chip above.